Celldex Therapeutics, Inc. (CLDX) Profit Margins
Over the twelve months to 2026-06-30, Celldex Therapeutics, Inc. (CLDX) had operating margin -206220.3%, net margin -190220.9%, free cash flow margin -153231.0%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CLDXCelldex Therapeutics, Inc.Follow CLDX — free
—
Price chart with a free account
- Market cap
- 2.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | 92.7% | 97.2% | 97.3% | 97.8% | 95.8% | 95.6% | 97.2% | 87.1% | — | |
| Operating margin | -468.4% | -518.5% | -1981.1% | -3414.1% | -2363.9% | -1958.7% | -953.7% | -1640.1% | -1540.2% | -854.1% | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -18599.8% | -206220.3% | |
| Net margin | -483.5% | -527.8% | -1983.7% | -3292.8% | -2321.1% | -1894.0% | -730.1% | -1585.1% | -1424.0% | -805.9% | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -16748.0% | -190220.9% | |
| FCF margin | -390.4% | -447.1% | -1748.7% | -2885.3% | -1893.5% | -1706.3% | -798.2% | -797.3% | -1319.5% | -565.6% | -1336.4% | -4478.6% | -1585.2% | -2274.9% | -13829.1% | -153231.0% |
USD millions · SEC XBRL
Celldex Therapeutics, Inc. — questions
- What is Celldex Therapeutics, Inc.'s operating margin?
- -206220.3% over the twelve months to 2026-06-30.
- What is Celldex Therapeutics, Inc.'s net profit margin?
- -190220.9% over the twelve months to 2026-06-30.
Every figure on this page comes from Celldex Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.